Cereno Scientific

The abstract titled “The eicosanoid analogue CS585 represents a first-in-class in prevention of platelet activation and thrombosis through direct activation of the prostacyclin receptor”, was authored by Michael Holinstat, Adriana Yamaguchi, Sylviane Lambert, Pooja Yalavarthi, Livia Stanger, Andrew Rickenberg, and Andrew White at University of Michigan, Ann Arbor, MI, US; Björn Dahlöf and Niklas Bergh at Cereno Scientific and University of Gothenburg. The abstract has been selected as an oral presentation and will be presented by Adriana Yamaguchi.

The scientific conference Vascular Discovery 2023: From Genes to Medicine aims to provide a forum for the timely exchange of information about new and emerging scientific research in lipids and lipoproteins, arteriosclerosis, thrombosis, vascular biology, genomics, precision medicine, peripheral vascular disease, and vascular surgery. It is organized by the American Heart Association; a non-profit organization working to promote cardiovascular health and improve the lives of people affected by heart disease and stroke. Their work includes funding innovative research, providing evidence-based guidelines for healthcare professionals, and educating individuals and communities on the importance of heart-healthy lifestyles.

Details on the oral presentation at the conference:

Presentation Title: The eicosanoid analogue CS585 represents a first-in-class in prevention of platelet activation and thrombosis through direct activation of the prostacyclin receptor

Authors: Michael Holinstat, Adriana Yamaguchi, Sylviane Lambert, Pooja Yalavarthi, Livia Stanger, Andrew Rickenberg, and Andrew White, University of Michigan, Ann Arbor, MI, USA; Björn Dahlöf and Niklas Bergh, Cereno Scientific and University of Gothenburg, Gothenburg, Sweden.

Presentation Number: 122

Session Title: Concurrent Session 2b: Thrombosis: Signaling, Mechanisms & Function

Presentation Date: May 11, 2023

Presentation Time: 5:30 PM – 5:45 PM

Session Location: Boston Marriott Copley Place Hotel in Boston, Massachusetts, US

For further information, please contact:

Josefine Göranson, Head of IR & Communication
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/

About Cereno Scientific AB

Cereno Scientific is a clinical-stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects, selected for prevention of thrombosis as target indication. In preclinical studies it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. Thrombosis prevention in venous or arterial and cardiovascular disease has been selected as the first indication area for CS014. Drug candidate CS585 is a stable, selective, and potent prostacyclin receptor agonist. It has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.